The Impact of Biomarkers and Surrogate End Points on Regulatory Approval of New Drugs

Publisher： Karger

E-ISSN： 1424-0556|2|5|235-245

ISSN： 1422-9528

Source： Heart Drug, Vol.2, Iss.5, 2003-01, pp. : 235-245

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biomarkers: diagnostic highlights and surrogate end points

By Levenson Victor V  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 459-461

Future Medicine

Access to resources Recommend Favorite

US physicians eagerly await approval of new HCV drugs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 616, 2010-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Is the UK government delaying approval for new cancer drugs?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 649, 2012-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Surrogate End Points of Antihypertensive Treatment: Left Ventricular Hypertrophy and Structural Alteration of Carotid Arteries

By  

Heart Drug, Vol. 1, Iss. 2, 2004-11 ,pp. : 89-95

Karger

Access to resources Recommend Favorite

Biological marker no surrogate for response in accelerated approval

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite